ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly and Company will pay Foghorn Therapeutics, a 5-year-old biotech firm, $300 million and buy $80 million of its stock as part of a collaboration to create oncology drugs that target the chromatin regulatory system. In particular, the two companies will codevelop small-molecule BRM inhibitors that Lilly calls a “difficult chemistry challenge.” Separately, Lilly will pay 3-year-old Regor Therapeutics up to $50 million as part of an agreement to develop small-molecule therapies for metabolic disorders using Regor technology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter